In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 966-968

  Munoz Bellido J L ^a   Alonso Manzanares, M A ^a   Yague Guirao G Y ^b   Gutierrez Zufiaurre M N ^a   Toldos, M C M ^b   Segovia Hernandez M ^b   Garcia Rodriguez J A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; CLINAFLOXACIN; DIFLOXACIN; ENOXACIN; FLEROXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLONE; SPARFLOXACIN; TOSUFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; DRUG MECHANISM; DRUG POTENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0344457378     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.966     Document Type: Article

References (18)

1. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
2. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
3. Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
4. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885.
5. Hooper, D. C. 1998. Structure of grepafloxacin relative to activity and safety profile. Clin. Microbiol. Infect. 4(Suppl. 1):S15-S20.
6. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38: 2014-2023.
7. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
8. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92:11801-11805.
9. Marriott, M. S. 1998. Grepafloxacin: microbiological properties. Clin. Microbiol. Infect. 4(Suppl. 1):S9-S14.
10. Martínez, J. A., G. Ortiz, M. Segovia, M. A. Alonso, M. N. Gutiérrez, J. L. Muñoz, and J. A. García-Rodríguez. 1998. Analysis of grlA mutations in clinical isolates of Staphylococcus aureus with different levels of quinolone resistance. Antimicrob. Agents Chemother. 42:1306-1307.
11. National Committee for Clinical Laboratory Standards. 1993. Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
12. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparftoxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
13. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
14. Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Lackefahr, M. Klootwijk, J. Verhoef, A. Fluit, H. P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY-12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:481-484.
15. Sreedharan, S., M. Oram, B. Jensen, L. R. Peterson, and L. M. Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J. Bacteriol. 172:7260-7262.
16. Sugino, A., C. L. Peebles, K. N. Kreuzer, and N. R. Cozzarelli. 1977. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA 74:4767-4771.
17. Takenouchi, T., F. Tabata, Y. Iwata, H. Hanzawa, M. Sugawara, and S. Ohya. 1996. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1835-1842.
18. Vila, J., J. Ruiz, P. Goñi, and M. T. Jimenez de Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicob. Agents Chemother. 40:491-493.